MorphoSys AG Meet The Team · 2019-06-25 · MorphoSys AG Meet The Team The Yale Club, New York June 25, 2019

MorphoSys AG

Meet The Team

The Yale Club, New York

June 25, 2019

2© MorphoSys AG | Meet the Team | June 25, 2019

This presentation includes forward-looking statements.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies, including its financial guidance for 2019,

the commencement, timing and results of clinical trials and release of clinical data both in respect of its proprietary product candidates and of product

candidates of its collaborators, the development of commercial capabilities, in particular with respect to tafasitamab (MOR208) and the transition of

MorphoSys to a fully integrated biopharmaceutical company, interaction with regulators, including the potential approval of MorphoSys’s current or future

drug candidates, including discussions with the FDA regarding the potential approval to market tafasitamab, the expected time of launch of tafasitamab,

and expected royalty and milestone payments in connection with MorphoSys’s collaborations. The forward-looking statements contained herein represent

the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results,

financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future

results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if

MorphoSys’s results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such

forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are

that MorphoSys’s expectations regarding its 2019 results of operations may be incorrect, MorphoSys’s expectations regarding its development programs

may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory

approval requirements (including that MorphoSys may fail to obtain regulatory approval for tafasitamab and that data from MorphoSys’s ongoing clinical

research programs may not support registration or further development of its product candidates due to safety, efficacy or other reasons), MorphoSys’s

reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors

included in MorphoSys’s Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission. Given these uncertainties, the

reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of

publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any

change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may

affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or

regulation.

The compounds discussed in this slide presentation are investigational products being developed by MorphoSys and its partners and are not currently

approved by the U.S. Food and Drug Administration (FDA), European Medicine Agency (EMA) or any other regulatory authority (except for

guselkumab/Tremfya®). Any shown cross-trial comparison between MorphoSys-own investigational products and literature data have significant

limitations. Such data comparisons have been prepared at the request of, and for the sole benefit of, the investor community.


David Trexler, President MorphoSys US Inc.

Meet the Team | June 25, 2019


This presentation includes forward-looking statements.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies, including its financial guidance for 2019,

the commencement, timing and results of clinical trials and release of clinical data both in respect of its proprietary product candidates and of product

candidates of its collaborators, the development of commercial capabilities, in particular with respect to tafasitamab (MOR208) and the transition of

MorphoSys to a fully integrated biopharmaceutical company, interaction with regulators, including the potential approval of MorphoSys’s current or future

drug candidates, including discussions with the FDA regarding the potential approval to market tafasitamab, the expected time of launch of tafasitamab,

and expected royalty and milestone payments in connection with MorphoSys’s collaborations. The forward-looking statements contained herein represent

the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results,

financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future

results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if

MorphoSys’s results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such

forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are

that MorphoSys’s expectations regarding its 2019 results of operations may be incorrect, MorphoSys’s expectations regarding its development programs

may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory

approval requirements (including that MorphoSys may fail to obtain regulatory approval for tafasitamab and that data from MorphoSys’s ongoing clinical

research programs may not support registration or further development of its product candidates due to safety, efficacy or other reasons), MorphoSys’s

reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors

included in MorphoSys’s Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission. Given these uncertainties, the

reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of

publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any

change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may

affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or

regulation.

The compounds discussed in this slide presentation are investigational products being developed by MorphoSys and its partners and are not currently

approved by the U.S. Food and Drug Administration (FDA), European Medicine Agency (EMA) or any other regulatory authority (except for

guselkumab/Tremfya®). Any shown cross-trial comparison between MorphoSys-own investigational products and literature data have significant

limitations. Such data comparisons have been prepared at the request of, and for the sole benefit of, the investor community.

5

Strong history of top level performance

© MorphoSys AG | Meet the Team | June 25, 2019

Commercial Leadership

David Trexler

President of MorphoSys US Inc.

33 year track record in building commercial capabilities

for international pharmaceutical companies

Prior positions as SVP Oncology Commercial for EMD

Serono/Merck KGaA building first commercial oncology

footprint in the U.S. and launching the first PD-L1

antibody for mMCC. Other positions, including Eisai Inc,

being responsible for commercial strategies, supporting

Aloxi®, Dacogen®, Halaven® and Lenvima®

Deep knowledge of marketing, sales, market access

environment and business development

Focus on build-up of MorphoSys’s commercial capabilities

in preparation for the planned tafasitamab launch


We are building a strategic presence in

the world‘s most important pharmaceutical market

7

1) IQVIA MIDAS May 2018 2) IQVIA patient survey June 2018

Accelerated market uptake from U.S. hub


U.S. Commercialization Strategy

U.S. Market Size1)

64% of sales of all new medicines

launched between 2012-2017

48% of global sales (~$853 bn) in 2017

Large Oncology Network2)

Top 10 U.S. states contain 56% of all

DLBCL patients and 55% of all treaters

8

Building the tafasitamab value chain between the U.S. and Europe


Leveraging Synergies

Contributing strong commercial expertise

U.S. Head of Market Access and Policy

U.S. Marketing and Sales

U.S. Medical Affairs

Munich

Boston

MorphoSys AG

MorphoSys US Inc.

Contributing strong technology expertise

Global Head of Supply Chain Management

Global Head of Regulatory

Antibody material produced in Germany

Packaging of tafasitamab planned in Europe

9

Laying a foundation for the anticipated launch of tafasitamab in the U.S.


U.S. Commercial Strategy

Functional Commercial Structure

Filling critical positions by hiring talents with deep expertise

Targeted Market Access and Policy Approach

Securing timely and appropriate access to tafasitamab

>200

Commercial Operations Build-up

Providing an operational foundation to enable market access

Sales and Marketing Approach

Position tafasitamab as potential new standard of care

in r/r DLBCL

10

Filling critical positions by hiring talent with deep expertise


Functional Commercial Structure

Medical Affairs

Nuwan Kurukulasuriya

Market Access and Policy

Chris Mancill

Legal

Ben Looker

Finance

Chris Krawtschuk

Commercial Operations

Krishna Kadiyala

Sales and Marketing

Stephane Berthier

President

MorphoSys US Inc.

David Trexler

11

Recruiting top talent to build a function fit for strong launch


Top Talent

25 years experience in market access, policy,

and pricing at the global and U.S. levels

Prior positions with numerous biopharmaceutical

companies, including Amgen and EMD Serono/Merck KGaA

Proven track record of securing access for innovative

oncology products, matching the buy-and-bill, HCP-

administered profile of tafasitamab

Deep experience in oncology and hematology launches

across a large variety of indications and tumor types

Chris Mancill

Senior Vice President and Head

of Market Access and Policy

12

HCP – Health care professionals CMS – Centers for Medicare & Medicaid

Striving to enable access to tafasitamab for all eligible patients


Strategic Imperatives

Market Approach Policy Approach

Make tafasitamab easily available to HCPs

in community and academic settings

Ensure payer awareness through targeted pre-

approval engagement and secure CMS coding

Address barriers among HCPs to grant

timely patient access

Support appropriate patient access with financial

and other patient support resources

Brand MorphoSys as a responsible partner

in addressing policymaker’s priorities

Embed advocacy community perspectives

into the commercialization plan

Understand the pricing and reimbursement

landscape to inform launch plans

Ensure that stakeholder views are considered

in our patient access and support approach

13



Top Talent

14 years experience in creating value with

commercial operations and advanced analytics

Prior positions in a variety of biopharmaceutical

companies, including Spectrum, Novartis and Merck

Proven track record of developing commercial strategies

for maximizing short- and long-term value of the brand

Deep experience in oncology and hematology launches

across a variety of indications and tumor types

Krishna Kadiyala

Vice President and Head of

Commercial Operations and

Innovation

14

Laying a solid operational foundation to enable market access



Commercial building blocks

Enable sales and marketing to increase awareness

of tafasitamab among customers and patients

Implement cutting-edge technology and advanced

analytics to create competitive advantage

Deliver solutions to decrease barriers to adoption

Develop and continuously improve sales

management processes through innovation

Commercial Operations

Execute on roadmap for market segmentation

and sales force size and structure

Evaluate commercial technologies to enable

multiple sales and marketing touch points

Build commercial analytics function to shape

commercial strategy, life cycle management,

and resource allocation decisions

15



Top Talent

20 years experience in global and U.S. sales & marketing

and global research & development

Prior positions at Novartis and at Janssen where being

responsible for the Imbruvica® franchise

Strong scientific and business qualifications and proven

track record of leading sales & marketing teams and cross-

functional teams

Deep expertise in oncology and hematology with more

than 15 year experience in developing, launching and

maximizing drugs

Stephane Berthier

Vice President and Head of

Sales and Marketing

16

1) Subject to approval HCP - Healthcare professionals

Establish tafasitamab as potential new standard of care in r/r DLBCL1)



Sales and Marketing Approach

Support quick adoption of tafasitamab

at launch

Establish tafasitamab + lenalidomide as

potential standard of care in r/r DLBCL1)

Institute treat-to-progression in r/r DLBCL

Set up MorphoSys as a strong partner to key

oncology accounts and institutions

High performing field force communicates value of

tafasitamab and overcomes early access challenges

Tafasitamab + lenalidomide intended to allow for

convenient and long term disease control for

patients and HCPs

Tafasitamab + lenalidomide tolerability implies

potential benefit on long term treatment efficacy

Be seen by all stakeholders as a reliable

company caring for the needs of their patients


Summary

Building-up of an efficient organization to prepare

for a potential U.S. launch of tafasitamab

Tapping the full potential of MorphoSys by addressing

the world’s most important pharmaceutical market

Creating an environment that attracts, develops

and retains best-in-class talent

SUMMARY

Documents

MorphoSys AG Meet The Team · 2019-06-25 · MorphoSys AG Meet The Team The Yale Club, New York June 25, 2019